The Judicial Panel on Multidistrict Litigation (JPML) announced that it will hear arguments on January 25, 2018 regarding whether to centralize federal lawsuits filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). (To review the JPML’s Hearing Session Order click here.) Saxagliptin is part...
Heart Failure from Diabetes Drugs, Onglyza & Kombiglyze- LITIGATION UPDATE
Multiple lawsuits have been filed by individuals who have suffered heart failure after taking the diabetes drug saxagliptin (marketed as Onglyza and Kombiglyze XR). Saxagliptin is part of the class of dipeptidyl peptidase-4 (DPP-4) inhibitor drugs, which are used with diet and exercise to lower blood sugar in adults with type 2 diabetes. (These medicines...